small molecule

INOMAX

NITRIC OXIDE

Loss of exclusivityJune 2029latest FDA-listed patent expiry
CompanyMALLINCKRODT PHARMACEUTICALS IRELAND LTD

Drug detail

Brand nameINOMAX
Active ingredientNITRIC OXIDE
Strength4880PPM
Dosage formGAS
RouteINHALATION
ModalitySmall molecule
FDA approvalJanuary 2023
Marketing statusRX

Listed patents

PatentExpiresType
11931377June 2029substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INOMAX patent cliff — loss of exclusivity June 2029 | CliffBio